IMMX · Immix Biopharma Inc
United States · RS rating 36 · As of 2026-10-14
| Price | 8.51 USD |
|---|---|
| 1-day change | -2.1% |
| RS rating (overall / 1M / 3M / 12M) | 36 / 6 / 24 / 98 |
| Stage | Basing |
| Composite / Minervini / CANSLIM score | 34 / 35 / 20 |
| Industry group (rank) | Medical-Biomed/Biotech (167) |
| EPS growth Q/Q | +0.0% |
| Sales growth Q/Q | – |
| Distance from 52-week high | +41.2% |
| Market cap (USD) | $539.1M |